agilon health, inc. (AGL) Analyse boursière

Présentation de l'entreprise

Agilon Health, Inc. operates within the healthcare sector, specifically serving the medical care facilities industry by delivering primary care services to seniors through a network of physicians across the United States. The company utilizes a subscription-based per-member-per-month model to manage the comprehensive healthcare needs of its patient population, aiming to provide continuous and integrated care solutions. This operational scale is reflected in a market capitalization of $306.71M and an annual revenue generation of $5.93B over the trailing twelve months. With an employed workforce of 856 individuals, the firm's market cap and revenue figures suggest a mid-sized enterprise that has achieved significant top-line scale despite recent profitability challenges. The substantial revenue base relative to its market cap indicates a company that may be in a growth or investment phase where cash reinvestment is prioritized over immediate profit expansion.

Santé financière

Agilon Health reported a revenue of $5.93B for the trailing twelve months, while simultaneously posting a net income loss of $405,347,008 and an EBITDA of $-406,182,016. The significant gap between the substantial revenue figure and the negative net income reveals a cost structure where operating expenses and losses heavily outweigh gross earnings, resulting in a gross margin of -2.7%. This negative gross margin indicates that the cost of goods sold exceeds revenue, while the operating margin of -10.0% and profit margin of -6.6% further demonstrate that fixed costs and overhead are consuming the majority of the top line before reaching the bottom line. The company's free cash flow stands at $-81,226,128, which signifies a lack of financial flexibility as the business is currently burning cash rather than generating liquidity to fund operations or debt service. On the balance sheet, the firm holds $285.14M in cash against a debt obligation of $36.81M, supported by a debt-to-equity ratio of 29.05, which suggests a leveraged position where equity is the primary buffer against liabilities. Despite the high leverage ratio, the current ratio of 1.02 indicates that the company's short-term liquid assets are only marginally higher than its current liabilities, pointing to a tight liquidity position with limited cushion for immediate obligations. The return on equity is reported at -135.6% and the return on assets at -17.5%, metrics that reveal management has yet to generate positive returns on the capital invested, highlighting the challenges in achieving profitability within the current operational framework.

Évaluation de la valorisation

Valuation metrics for Agilon Health present a complex picture given the negative earnings, with a trailing P/E ratio listed as N/A due to the lack of positive net income and a forward P/E of -4.33. The discrepancy between the non-existent trailing earnings and a negative forward P/E implies that the market is pricing in a future trajectory where earnings remain negative or where valuation is based on book value rather than earnings power. The price-to-book ratio is stated at 2.42, indicating that the market is valuing the company at a premium of 142% over its net book value, which often occurs in sectors where intangible assets or future growth potential are expected to drive value despite current losses. Alternative valuation measures such as the price-to-sales ratio of 0.05 and an EV/EBITDA of -0.14 suggest that the stock is priced very low relative to its massive sales volume, though these metrics are distorted by the negative earnings and cash flow dynamics. The stock's price has fluctuated significantly within its 52-week range, trading between a high of $152.00 and a low of $7.48, meaning the current trading price sits near the bottom of this historical range relative to the peak valuation observed in the last year. The beta value of 0.33 indicates that the stock's price volatility is substantially lower than the broader market, suggesting it behaves more as a defensive or low-volatility asset in the short term, although this low beta is often associated with distressed or non-cyclical growth names.

Growth & Income

Agilon Health has demonstrated a revenue growth rate of 3.1% year-over-year, while earnings growth is marked as N/A due to the persistent losses, implying that top-line expansion is currently decoupled from profitability. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all available capital and retained earnings back into the business to fund its expansion and operational losses rather than distributing income to shareholders. This strategy of retaining earnings instead of paying dividends is typical for companies in the medical care facilities sector that are prioritizing market share growth and infrastructure development over immediate shareholder returns. The overall growth and income profile characterizes Agilon Health as a high-growth, non-dividend payer that relies on external capital markets or cash reserves to sustain operations while it works toward achieving positive earnings and cash flow generation.